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Abstract
Introduction: Many	patients	with	von	Willebrand	disease	(VWD)	are	treated	on	de‐
mand	with	von	Willebrand	factor	and	factor	VIII	(FVIII)	containing	concentrates	pre‐
sent	with	VWF	and/or	FVIII	plasma	levels	outside	set	target	levels.	This	carries	a	risk	
for	bleeding	and	potentially	for	thrombosis.	Development	of	a	population	pharma‐
cokinetic	(PK)	model	based	on	FVIII	levels	is	a	first	step	to	more	accurate	on‐demand	
perioperative	dosing	of	this	concentrate.
Methods: Patients	 with	 VWD	 undergoing	 surgery	 in	 Academic	 Haemophilia	
Treatment	Centers	in	the	Netherlands	between	2000	and	2018	treated	with	a	FVIII/
VWF	plasma‐derived	concentrate	(Haemate®	P/Humate	P®)	were	included	in	this	
study.	Population	PK	modeling	was	based	on	measured	FVIII	levels	using	nonlinear	
mixed‐effects	modeling	(NONMEM).
Results: The	population	PK	model	was	developed	using	684	plasma	FVIII	measure‐
ments	of	97	VWD	patients	undergoing	141	surgeries.	Subsequently,	the	model	was	
externally	 validated	 and	 reestimated	 with	 independent	 clinical	 data	 from	 20	 ad‐
ditional	patients	undergoing	31	 surgeries	 and	208	plasma	measurements	of	FVIII.	
The	 observed	 PK	 profiles	 were	 best	 described	 using	 a	 one‐compartment	 model.	
Typical	values	for	volume	of	distribution	and	clearance	were	3.28	L/70	kg	and	0.037	
L/h/70	kg.	Increased	VWF	activity,	decreased	physical	status	according	to	American	
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1  | INTRODUC TION
Von	Willebrand	disease	(VWD)	is	the	most	common	inherited	bleeding	
disorder	diagnosed	in	humans.1 This autosomally inherited disorder is 
characterized	by	quantitative	or	qualitative	defects	of	Von	Willebrand	
factor	(VWF)	and	concomitant	lower	FVIII	levels.	Von	Willebrand	fac‐
tor	is	essential	for	both	primary	and	secondary	hemostasis	as	it	con‐
tributes	to	platelet	adhesion	and	aggregation	at	sites	of	injury,	resulting	
in	platelet	plug	formation.	Moreover,	it	acts	as	a	chaperone	protein	for	
FVIII,	protecting	it	from	proteolysis	in	the	circulation.2,3
The	current	VWD	classification	is	based	on	observed	VWF	ab‐
normalities.	Whereas	 type	 1	 VWD	 describes	 a	 partial	 and	 type	 3	
VWD	a	complete	quantitative	VWF	deficiency,	 type	2	VWD	com‐
prises	 several	 qualitative	 VWF	 defects.	 Von	Willebrand	 disease	 is	
mainly	characterized	by	mucocutaneous	bleeding	and	bleeding	after	
trauma	or	surgery.	Available	treatment	focuses	on	normalization	of	
VWF	and	FVIII	levels	in	cases	of	acute	bleeding,	when	trauma	occurs,	
or	in	surgery.	The	VWF	and	FVIII	levels	can	be	increased	by	admin‐
istration	of	desmopressin,	which	stimulates	endogenous	release,	or	
by	replacement	therapy	with	intravenously	administered	exogenous	
VWF	concentrate	with	or	without	FVIII.4	Prophylactic	treatment	is	
rarely	necessary	and	usually	restricted	to	type	3	VWD	patients.
A	 widely	 used	 plasma‐derived	 VWF	 concentrate	 in	 patients	
with	VWD	is	Haemate	P®	or	Humate	P®.5 This concentrate contains 
both	VWF	and	FVIII	in	a	ratio	of	2.4:1.	Interindividual	variability	in	
achieved	 levels	 after	 infusion	 of	 this	 VWF/FVIII‐containing	 con‐
centrate	 has	 been	 reported	 by	 several	 investigators,	 both	 in	 the	
on‐demand	treatment	of	bleeding	and	in	the	surgical	setting.6‐9 This 
variability	can	be	explained	by	both	the	 interindividual	differences	
in	PK	of	the	exogenous	VWF/FVIII‐containing	concentrate	and	the	
interindividual	 differences	 in	 residual	 endogenous	VWF	 and	 FVIII	
levels.	Moreover,	endogenous	FVIII	levels,	which	are	known	to	vary	
unpredictably	because	of	FVIII	release	from	the	endothelium	after	
induced	stress,	trauma,	or	surgery,	can	differ	significantly	within	an	
individual	patient	and	between	individuals.	This	variability	hampers	
adequate	dosing	of	VWF/FVIII	concentrate,	leading	to	achieved	lev‐
els	 that	may	be	higher	or	 lower	 than	 targeted.6	 Subsequently	 this	
may	lead	to	an	increased	risk	of	thrombosis	or	bleeding,	respectively.	
In	addition,	patient	and	societal	burden	of	treatment	are	unnecessar‐
ily	high	as	a	result	of	frequent	monitoring	of	plasma	FVIII	and	VWF	
levels	and	more	consumption	of	concentrate	than	necessary.6
The	current	challenges	to	achieve	the	required	target	levels	in	VWD	
patients	using	 this	 specific	VWF/FVIII	 concentrate	 call	 for	 additional	
tools	to	dose	more	adequately.	Population	PK	modeling	and	subsequent	
maximum	 a posteriori	 Bayesian	 analysis	 could	 be	 promising	 tools	 to	
reach	individualize	care	in	VWD	patients	who	need	to	undergo	surgery.
Historically,	perioperative	dosing	of	VWD	patients	with	VWF/
FVIII	concentrates	has	been	based	on	FVIII	 levels	for	a	variety	of	
reasons.	First,	generally	FVIII	plasma	 levels	were	presumed	more	
important	in	preventing	perioperative	bleeding.10	Second,	product	
labels	only	 contained	 information	on	FVIII	 potency.	Finally,	more	
practically,	the	more	rapid	availability	of	FVIII	level	results	in	most	
laboratories	made	FVIII‐based	dosing	a	more	feasible	guide	for	re‐
placement	therapy	with	VWF/FVIII	concentrate.	However,	nowa‐
days	some	researchers	recommend	that	especially	during	the	first	
36	postoperative	hours,	VWF	activity	also	needs	to	be	measured	
because	 the	 presence	 of	 sufficient	 VWF	 activity	 can	 be	 import‐
ant	for	the	aggregation	of	platelets	during	primary	hemostasis	and	
therefore	initial	wound	closure.3,11	Sufficient	FVIII	 levels	are	sub‐
sequently	required	for	complete	wound	healing	and	are	therefore	
often	monitored	during	the	whole	perioperative	period.12‐14 Dutch 
national	guidelines	have	adopted	these	general	principles	and	de‐
scribe	FVIII	and	VWF	targets	for	the	first	36	h	after	the	surgery	and	
FVIII	targets	for	the	further	monitored	postoperative	period.13The 
aim	of	the	study	is	to	assess	the	population	PK	of	FVIII	activity	lev‐
els	after	perioperative	administration	of	a	specific	VWF/FVIII	con‐
centrate	and	to	identify	any	patient,	surgical,	or	treatment	factors	
Society	of	Anesthesiologists	(ASA)	classification	(ASA	class	>2),	and	increased	dura‐
tion	of	surgery	were	associated	with	decreased	FVIII	clearance.
Conclusion: This	population	PK	model	derived	from	real	world	data	adequately	de‐
scribes	FVIII	levels	following	perioperative	administration	of	the	FVIII/VWF	plasma‐
derived	concentrate	(Haemate®	P/Humate	P®)	and	will	help	to	facilitate	future	dosing	
in	VWD	patients.
K E Y W O R D S
Haemate	P,	individualized	medicine,	pharmacokinetics,	surgery,	von	Willebrand	disease
Essentials
•	 In	many	Von	Willebrand	disease	(VWD)	patients,	periop‐
erative	factor	VIII	(FVIII)	and	von	Willebrand	factor	levels	
are	outside	set	targets.
•	 A	 population	 pharmacokinetic	 model	 for	 Haemate	 P	
based	on	FVIII	levels	was	developed.
•	 The	FVIII	levels	after	Haemate	P	administration	were	ad‐
equately	 described	 by	 the	 population	 pharmacokinetic	
model.
•	 The	 population	 pharmacokinetic	 model	 could	 facilitate	
more	accurate	perioperative	dosing	for	VWD	patients.
     |  3de JAGeR eT AL.
correlating	with	the	PK	parameters	of	FVIII.	The	population	model	
can	 be	 a	 starting	 point	 for	 the	 individualization	 of	 replacement	
therapy	during	the	perioperative	period	in	VWD	patients	and	may	
be	especially	useful	when	only	FVIII	targets	apply.
2  | METHODS
2.1 | Data
The	data	used	to	construct	this	population	PK	model	were	obtained	
from	 a	multicenter	 retrospective	 cohort	 study	 performed	 by	 the	
OPTI‐CLOT	study	group,	conducted	in	five	Academic	Haemophilia	
Treatment	 Centers	 in	 the	 Netherlands.6	 This	 first	 data	 set	 is	 re‐
ferred	to	as	 the	 index data set	and	was	used	for	 the	development	
of	this	FVIII‐based	population	PK	model.	Additionally,	an	extra	data	
set	from	the	Erasmus	University	Medical	Center	Rotterdam	(n	=	20)	
was	collected;	it	was	used	for	external	validation	of	the	developed	
FVIII‐based	population	PK	model.	This	data	set	will	be	referred	to	as	
the validation data set.	The	combination	of	both	data	sets	was	used	
to	build	 the	 final	FVIII‐based	population	PK	model.	All	data	were	
collected	between	2000	and	2018	and	acquired	in	accordance	with	
the	Dutch	rules	and	regulations	for	Good	Clinical	Practice.
All	VWD	patients	included	in	this	study	underwent	a	surgical	 in‐
tervention	requiring	replacement	therapy	with	VWF/FVIII	concentrate	
(Haemate	P®).	The	data	consisted	of	FVIII	plasma	levels,	patient	demo‐
graphics,	 surgical	characteristics,	and	 treatment	 information.	Patient	
demographics	included	sex,	age,	height,	weight,	blood	group,	hemoglo‐
bin	levels,	baseline	VWF:antigen	(VWF:Ag),	VWF	activity	(VWF:Act),	
and	FVIII	activity	 levels	 (lowest	 levels	ever	measured	in	the	patient),	
renal	 function	and	hepatic	 function	 (characterized	by	aspartate	ami‐
notransferase,	alanine	aminotransferase,	gamma	glutamyl	transferase,	
alkaline	phosphatase,	lactate	dehydrogenase,	albumin,	urea,	and	cre‐
atinine),	type	of	VWD	as	diagnosed	following	the	national	guidelines,	
and	surgical	risk	classification	based	on	the	ASA	physical	status	classi‐
fication	system.13	Surgical	characteristics	consisted	of	 type,	severity	
and	duration	of	surgery.15	Treatment	information	described	timing	and	
dosing	of	the	concentrate	and/or	comedication	with	effect	on	hemo‐
stasis	(nonsteroidal	antiinflammatory	drug,	tranexamic	acid,	or	hepa‐
rin)	and	achieved	FVIII,	VWF:Act,	VWF:Ag,	and	VWF:collagen	binding	
levels.	Perioperative	dosing	of	the	VWF/FVIII	concentrate	was	based	
on	FVIII	levels,	which	were	measured	by	one‐stage	clotting	assays.13 
Dosages	and	levels	obtained	after	additional	desmopressin	use	were	
excluded,	 as	 FVIII	 pharmacokinetics	 after	 desmopressin	 were	 ex‐
pected	to	deviate	as	a	result	of	excessive	endogenous	FVIII	release.16 
The	included	patients	did	not	receive	prophylactic	treatment	and	when	
occasionally	a	dose	was	given	before	the	loading	dose	of	the	surgery,	
this	dose	was	included	in	the	database.	A	more	detailed	overview	of	
data characteristics is documented in Table 1.
2.2 | Population PK modeling
The	 population	 PK	 modeling	 approach	 analyzes	 the	 data	 from	 all	
patients	 simultaneously	 instead	 of	 modeling	 individual	 patients	
separately.	An	analysis	provides	typical	(median)	values	of	PK	parame‐
ters	and	the	corresponding	interindividual	and	intraindividual	variabil‐
ity.	With	this	method	sparse	data	with	random	sampling	times,	which	
usually	are	present	during	clinical	data	collection,	can	be	analyzed.
A	compartmental	population	PK	model	describing	the	PK	of	FVIII	
levels	 after	 administration	 of	 this	 specific	 VWF/FVIII	 concentrate	
in	 the	 perioperative	 setting	was	 developed	 using	 nonlinear	mixed	
effect	 modeling,	 as	 implemented	 in	 software	 package	 NONMEM	
version	7.4.2	(ICON	Development	Solution).	Visualization	and	eval‐
uation	of	the	data	and	the	developed	FVIII	PK	model	were	achieved	
using	R	v3.4.1	and	PsN	v4.7.0	in	combination	with	Piraña	v2.9.6.17‐20 
Factor	VIII	levels	were	log	transformed	and	after	analysis	the	PK	pa‐
rameters,	their	interindividual	variability	(IIV),	and	residual	variability	
between	observed	and	predicted	FVIII	were	derived.	In	order	to	de‐
termine	what	number	of	compartments	produced	the	best	fit	of	the	
data,	single	and	multiple	compartment	linear	models	were	used	to	fit	
the	FVIII	versus	time	data.	The	PK	parameters,	volume	of	distribu‐
tion	(V)	and	clearance	(CL),	were	estimated.	When	using,	for	exam‐
ple,	a	two‐compartment	model,	estimation	of	the	peripheral	volume	
of	distribution	and	intercompartmental	clearance	was	included.
Baseline	FVIII	was	estimated	 in	 the	PK	analysis	and	subtracted	
from	the	observed	FVIII	level	in	the	modeling	process,	though,	in	92	
of	the	180	surgeries,	FVIII	was	measured	before	administration	of	the	
VWF/FVIII	concentrate	and	these	values	did	not	always	coincide	with	
the	measured	baseline	FVIII:	That	is,	FVIII	before	administration	was	
often	higher	than	the	lowest	value	ever	measured	in	the	patient.	This	
difference	 is	most	 likely	 caused	by	physiological	 variability	 in	FVIII	
levels	or	by	preoperative	anxiety,	increasing	age,	or	presence	of	co‐
morbidity.21‐23	For	modeling	purposes,	a	correction	was	 introduced	
by	administration	of	a	fixed	virtual	dose	with	varying	bioavailability	to	
these	patients	prior	to	the	time	of	measurement	of	the	predose	FVIII	
level.	Application	of	this	technique	causes	FVIII	estimation	to	return	
to	the	lowest	value	ever	measured	instead	of	FVIII	 level	before	ad‐
ministration.	The	rationale	of	the	use	of	this	technique	was	strength‐
ened	by	the	presence	of	lower	FVIII	levels	at	the	end	of	perioperative	
treatment	than	before	dose	FVIII	was	measured	 in	10	occasions.	 It	
was	possible	to	estimate	the	bioavailability	(F)	and	its	variability	as	a	
correction	without	influencing	estimations	of	other	PK	parameters.
Finally,	as	a	wide	variatiety	of	ages	and	weights	was	present	in	
the	data,	the	PK	parameters	were	a priori	scaled	to	a	body	weight	of	
70	kg	using	the	allometric	scaling	principle.24
2.3 | Covariate modeling
In	order	to	test	the	capability	of	the	factors	sex,	age,	height,	blood	
group,	duration	and	severity	of	surgical	procedure,	VWD	type,	ASA	
classification,	(baseline)	VWF:Act,	(baseline)	VWF:Ag,	VWF:CB,	use	
of	 nonsteroidal	 anti‐inflammatory	 drugs,	 tranexamic	 acid	 and/or	
heparin,	 and	 altered	hepatic	 function	 and/or	 renal	 function	 to	ex‐
plain	the	IIV	or	interoccasion	variability	in	PK	parameter	estimates,	
a	covariate	analysis	using	a	 forward	 inclusion	and	backwardselimi‐
nation	method	was	performed.	Using	a	univariate	analysis,	poten‐
tial	covariates	could	be	 identified	and	subsequently	be	 included	 in	
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TA B L E  1  Characteristics	of	the	index	data,	validation	data,	and	combination	of	all	available	data
Demographics
Subset
index	data Validation	data All	available	data
Number	of	patients 97 ‐ 20 ‐ 117 ‐
Female	sex 66 (68%) 12 (60%) 78 (67%)
Age	(y) 50 (0.5‐82) 48.5 (6.0‐76.0) 50 (0.5‐82)
Height	(cm)a 173 (69‐194) 170 (120‐183) 172 (69‐194)
Weight	(kg) 76.0 (8.8‐118.0) 83.0 (24.0‐112.0) 77.0 (8.8‐118.0)
Blood	group	Oa 49 (51%) 9 (45%) 58 (50%)
Baseline	FVIII	level	(IUmL‐1) 0.41 (0.01‐0.97) 0.40 (0.1‐0.7) 0.41 (0.01‐0.97)
Baseline	VWF:Act	level	(IUmL‐1) 0.16 (0.0‐0.58) 0.11 (0.05‐0.31) 0.15 (0.0‐0.58)
Baseline	VWF:Ag	level	(IUmL‐1) 0.28 (0.0‐0.93) 0.22 (0.07‐0.56) 0.28 (0.0‐0.93)
Liver	function	disordersa 18 (19%) 1 (5%) 19 (16%)
Surgical	characteristics
Number	of	patients	undergoing
1	surgery 69 (71%) 13 (65%) 82 (70%)
2	surgeries 16 (16%) 5 (25%) 21 (18%)
3	surgeries 10 (10%) 1 (5%) 11 (9%)
4	surgeries 0 (0%) 0 (0%) 0 (0%)
5	surgeries 1 (1%) 1 (5%) 2 (2%)
6	surgeries 1 (1%) 0 (0%) 1 (1%)
Duration	of	procedure	(min) 71 (7‐470) 48 (10‐387) 65 (7‐470)
Number	of	occasions/surgeries 141 ‐ 31 ‐ 172 ‐
Diagnosis	per	occasion
Number	of	VWD‐type	diagnoses
1 66 (47%) 15 (48%) 81 (47%)
2A 34 (24%) 12 (39%) 46 (27%)
2B 8 (6%) 2 (6%) 10 (6%)
2M 17 (12%) 2 (6%) 19 (11%)
2N 8 (6%) 0 (0%) 8 (5%)
3 8 (6%) 0 (0%) 8 (5%)
Number	of	ASA	classificationsa
II 99 (82%) 27 (87%) 126 (83%)
III 21 (17%) 4 (13%) 25 (16%)
IV 1 (1%) 0 (0%) 1 (1%)
Severity	of	surgical	procedure
Minor 37 (26%) 12 (39%) 49 (28%)
Major 104 (74%) 19 (61%) 123 (72%)
Treatment	information
Haemate	P®	dosages	per	occasion 5 (1‐30) 7 (2‐20) 5 (1‐30)
FVIII	dose	(IU/kg) 22.1 (5.5‐66.1) 16.7 (5.6‐50.0) 20.8 (5.5‐66.1)
Tranexamic	acid	use	during	occasion 59 (42%) 9 (29%) 68 (40%)
NSAID	use	during	occasion 6 (4%) 3 (10%) 9 (5%)
Heparin	use	during	occasion 58 (41%) 12 (39%) 70 (40%)
Note: Data	expressed	as	frequency	(%)	or	median	(range).
Abbreviations:	ASA,	American	Society	of	Anesthesiologists;	FVIII,	factor	VIII;	NSAID,	nonsteroidal	antiinflamatory	drug;	VWD,	von	Willebrand	dis‐
ease;	VWF:Ag,	von	Willebrand	factor	antigen;	VWF:Act,	von	Willebrand	factor	activity.
aMissing	data	were	present	in	4.3%	height,	4.3%	blood	group,	18.8%	altered	hepatic	functioning,	and	11.6%	ASA	classifications	of	all	available	data.	
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a multivariate analysis.25	 Factors	 to	 be	 included	 in	 the	 covariate	
analysis	were	selected	when	respective	data	were	available	in	≥50%	
of	patients.	Therefore,	 in	our	study	hemoglobin	was	ultimately	ex‐
cluded	from	the	covariate	analysis.	For	the	time‐varying	covariates	
VWF:Act,	VWF:Ag,	and	VWF:CB,	the	 last	observation	carried	for‐
ward	method	was	applied.	This	method	assumes	the	last	measured	
observation	until	a	new	observation	is	known.	Periods	when	a	virtual	
loading	dose	was	estimated	were	handled	separately,	as	no	VWF/
FVIII	had	been	administrated	yet.	A	more	in‐depth	overview	of	the	
population	pharmacokinetic	modeling	can	be	found	in	Supplement	
1	in	Appendix	S1.
2.4 | Model evaluation and validation
The	predictive	performance	of	the	model	was	evaluated	by	visual	in‐
spection	of	the	goodness‐of‐fit	plots.	Furthermore,	visual	predictive	
checks	were	performed	in	order	to	validate	the	model	internally.	The	
evaluated	model	generated	(n	=	1000)	simulations	of	the	observed	
data,	where	after	 the	simulated	data	were	compared	with	 the	ob‐
served data.
Subsequently,	this	intermediate	PK	model	based	on	97	patients	
was	externally	validated	in	20	other	patients	by	fitting	the	validation	
data	set	without	reestimating	model	parameter	estimates.	Visual	in‐
spection	of	goodness‐of‐fit	plots	was	performed	and	the	predictive	
performance	of	the	intermediate	FVIII	PK	model	was	determined	by	
calculating	the	mean	percentage	error	(Equation	1)	and	mean	abso‐
lute	 percentage	 error	 (Equation	 2),	 respectively,	 representing	 bias	
and inaccuracy.
where Cpred	 represents	 the	 population	 predication,	Cipred the indi‐
vidual	predication,	and	Cobs	 the	observed	FVIII	 for	a	 total	number	
of	observations	(n).	The	bias	is	regarded	as	non‐significant	when	0	is	
included	in	the	confidence	interval.	Inaccuracy	below	the	arbitrary	
chosen	25%	was	accepted.
Subsequently,	the	FVIII	PK	model	was	fully	developed	after	re‐
estimation	of	all	parameter	values	using	all	data	resulting	in	the	final	
FVIII	PK	model.	Finally,	a	bootstrap	method	was	applied,	using	1000	
data	subsets	resampled	from	the	complete	original	data.
3  | RESULTS
From	 a	 total	 of	 97	 patients,	 684	 FVIII	 measurements	 were	 col‐
lected	and	used	for	model	building,	while	the	remaining	208	FVIII	
samples	 of	 20	 patients	were	 used	 for	 external	 validation	 of	 the	
developed	 model.	 Factor	 VIII	 levels	 after	 administration	 of	 the	
VWF/FVIII	 concentrate	 ranged	 from	 4.70	 IU/mL	 as	 highest	 top	
level	to	0.01	IU/mL	over	time.	Bolus	infusion	dosages	ranged	from	
5.5	to	66.1	 IU	FVIII/	kg	body	weight,	while	4.7%	of	 the	dosages	
were	given	as	continuous	infusion	with	doses	ranging	from	0.19	to	
4.2	IU/h/kg	body	weight.	Samples	were	collected	within	a	period	
of	146	h	before	surgery	and	524	h	postoperatively;	 the	majority	
of	the	samples	were	collected	up	to	168	h	after	the	surgery.	Each	
patient	received	at	least	one	bolus	or	continuous	infusion	and	was	
monitored	 for	 a	period	 ranging	 from	1	 to	22	days	 after	 surgery.	
The	median	number	of	FVIII	measurements	during	hospitalization	
was	 5	 (ranging	 from	 1	 to	 14).	 Younger	 patients	 were	 underrep‐
resented,	 as	 only	 seven	 children	with	 a	median	 age	 of	 14	 years	
(range:	 0.5‐16	 years)	 and	 median	 body	 weight	 of	 54	 kg	 (range:	
8.8‐107	kg)	were	included.	None	of	the	FVIII	samples	was	below	
the	 lower	 limit	 of	 quantification	 (0.01	 IU/mL).	 Hemostatic	 com‐
plications	 during	 surgery	were	 limited,	 as	 no	 thrombotic	 events	
were	reported	and	a	clinically	relevant	bleeding	occurred	in	only	
five	surgeries.	Additional	 information	can	be	found	 in	the	article	
describing	the	data.6
3.1 | Structural model
A	one‐compartment	linear	model	best	described	FVIII	PK	after	ad‐
ministration	of	 the	VWF/FVIII	concentrate	 in	a	perioperative	set‐
ting.	Allometric	scaling	 for	body	weight	was	applied	 to	V	and	CL.	
Parameter	F	successfully	corrected	for	the	difference	in	the	baseline	
FVIII	level	and	the	FVIII	level	observed	prior	to	the	surgical	proce‐
dure	without	 influencing	 the	estimation	of	 the	other	PK	parame‐
ters.	The	IIV	was	identified	in	PK	parameters	V	and	CL,	whereas	the	
interoccasion	variability	was	identified	in	F.	Furthermore,	a	correla‐
tion	coefficient	was	estimated	between	the	variability	of	V	and	CL.	
Estimated	values	of	this	structural	FVIII	PK	model	can	be	found	in	
Table 2.
3.2 | Covariate modeling
During	the	forward	inclusion	of	the	covariate	analysis,	statistically	
significant	 (P	<	 .05)	associations	were	 identified	between	covari‐
ates	surgery	duration,	ASA	classification	and	VWF:Act	levels	over	
time,	and	 the	PK	parameter	CL.	Backward	exclusion	 revealed	all	
associations	to	be	statistically	significant	(P	<	.01).	When	surgery	
duration	 increased	 from	 45	 to	 106	min	 (interquartile	 range),	 CL	
decreased	with	38%.	Additionally,	when	 the	VWF:Act	 increased	
from	 0.78	 to	 2.21	 U/mL	 (interquartile	 range	 of	 all	 measured	
VWF:Act	 levels),	CL	decreased	with	29%,	presumably	caused	by	
prevention	of	degradation	of	FVIII	by	binding	to	VWF.	The	asso‐
ciations	between	these	exponentially	modeled	covariates	and	CL	
are	visualized	in	Figure	1A.	In	Figure	1C	interindividual	variability	
in	CL	 is	plotted	against	VWF	activity	 level	and	surgery	duration.	
These	plots	 should	 show	no	 trend,	 as	 this	 indicates	 that	 the	co‐
variates	explain	the	variability	well.	Finally,	patients	 in	ASA	class	
III	or	IV	exhibited	a	44%	decrease	of	CL	in	comparison	to	patients	
in	ASA	class	II.
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3.3 | Model validation and evaluation
The	intermediate	PK	model	based	on	the	index	data	set	was	vali‐
dated	with	an	external	data	set.	The	bias	and	inaccuracy,	described	
by	the	MPE	and	MAPE,	were	found	to	be	−10.2%	(95%	CI:	−14.3	to	
−6.2)	and	13.0%	(95%	CI:	11.6‐14.4).	Therefore,	the	predictive	per‐
formance	of	the	model	 in	the	validation	data	set	showed	a	small	
bias	 and	acceptable	 inaccuracy.	The	goodness‐of‐fit	 plots	of	 the	
validation	(Supplement	1	in	Appendix	S1)	depict	the	same	results	
and	visualize	 the	small	bias	 seen	 in	population	prediction	versus	
the	observed	levels	plot	and	acceptable	inaccuracy	in	the	popula‐
tion	prediction	as	well	as	the	individual	prediction	versus	observed	
levels	plot.
Following	reestimation	of	the	parameters	using	all	data,	good‐
ness‐of‐fit	plots	(Figure	2)	indicated	that	the	final	FVIII	population	
PK	model	adequately	describes	FVIII	levels	of	the	total	study	pop‐
ulation.	In	these	plots	the	trend	lines	are	close	to	the	line	of	iden‐
tity,	 indicating	that	no	bias	 is	present	and	the	data	are	randomly	
distributed around the line y = x.	Figure	2A	shows	the	predicted	
FVIII	levels	based	on	the	population	PK	parameters	with	covariate	
adjustment.	 Since	 IIV	 is	 not	 taken	 into	 account,	 large	deviations	
from	 the	 line	y = x	 are	observed.	Figure	2B	displays	 the	 individ‐
ual	 predicted	 FVIII	 levels	 compared	 to	 the	 observed	 levels.	 The	
individual	 predicted	 levels	 are	 calculated	by	using	 the	 individual	
PK	parameters	estimated	by	Bayesian	analysis.	Smaller	deviations	
around the line y = x	 are	 observed	 as	 IIV	 of	 the	 PK	 parameters	
is	 taken	 into	 account.	However,	 residual	 error	 is	 still	 present.	 In	
Figure	2C,	D	the	conditional	weighted	residuals,	representing	the	
difference	between	the	observed	and	predicted	FVIII	 levels,	ver‐
sus	population	prediction	or	time	after	dose	are	shown.	The	vast	
majority	of	the	points	are	between	−2	and	+2	SD	without	a	trend,	
indicating	sufficient	model	performance.
Adequate	model	performance	of	the	final	FVIII	PK	model	is	visu‐
alized	using	a	prediction‐corrected	visual	predictive	check	(Figure	3).	
Bootstrap	 confirmed	 the	 robustness	 of	 the	 parameter	 estimates	
obtained	 in	 the	 final	FVIII	PK	model.	Estimated	parameters	of	 the	
intermediate	 and	 final	 validated	 FVIII	 PK	 model	 parameters	 and	
bootstrap	values	can	be	found	in	Table	2.
4  | DISCUSSION
The	 aim	 of	 this	 study	was	 to	 develop	 a	 population	 PK	model	 de‐
scribing	 FVIII	 levels	 after	 administration	 of	 a	 specific	 VWF/FVIII	
concentrate	 (Haemate	 P®/Humate	 P®)	 in	 a	 perioperative	 setting.	
Additionally,	using	covariate	analysis,	any	patient,	surgical,	or	treat‐
ment	factors	correlating	with	the	PK	parameters	of	the	developed	
model	were	identified.
A	 one‐compartment	 PK	 model	 was	 able	 to	 fit	 the	 available	
data	describing	FVIII	 levels	 after	 administration	of	 the	VWF/FVIII	
F I G U R E  1  Relation	between	clearance	and	A,	the	VWF	activity	level	and	B,	the	duration	of	surgery	in	the	population	PK	model	for	a	
specific	VWF/FVIII	concentrate	(Haemate	P®/	Humate	P®).	The	interindividual	random	effects	for	interindividual	variability	(ƞ)	show	no	
trend	when	plotted	against	VWF	activity	level	C,	and	duration	surgery	D,	demonstrating	the	appropriateness	of	the	covariates	to	explain	
variability.	FVIII,	factor	VIII;	PK,	pharmacokinetics;	VWF,	von	Willebrand	factor	
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concentrate	 in	 the	perioperative	setting.	Almost	all	 achieved	FVIII	
levels	 of	 included	 study	 patients	were	well	 above	 predefined	 tar‐
gets	as	stated	by	national	guidelines,	specifically	95.2%	during	the	
first	 36	 h	 and	 98.9%	 in	 the	 subsequent	 period.13	 Twenty‐five	 of	
the	 included	 patients	 showed	 excessive	 FVIII	 levels	 (>2.5	 IU/mL)	
during	the	perioperative	period,	 indicating	the	potential	benefit	of	
PK‐guided	dosing.	Some	studies	have	already	examined	application	
of	PK‐guided	dosing	of	this	specific	VWF/FVIII	concentrate	follow‐
ing	surgery.14,26	The	prospective	multicenter	trial	of	Lethagen	et	al14 
demonstrated	 feasibility	 in	 selection	 of	 the	 loading	 dose	 prior	 to	
elective	 surgery	based	on	 the	PK	profile	of	 the	patient.	However,	
the	study	of	Di	Paola	et	al.	observed	a	poor	correlation	between	the	
presurgical	and	postsurgical	In	Vivo	Recovery	(IVR)	values,	question‐
ing	the	potential	profit	of	PK‐guided	dosing.	However,	our	approach	
is	likely	superior	to	the	study	by	Di	Paola	et	al26,	in	which	PK‐guided	
dosing	of	this	VWF/FVIII	concentrate	with	a	standard	two‐compart‐
ment	PK	model	was	evaluated	without	taking	the	prior	information	
of	 the	 population	 and	 influences	 of	 covariates	 into	 account.26	 A	
covariate	 analysis	 is	 important	 as	 various	 international	 guidelines	
recommend	specific	FVIII	target	 levels	depending	on	the	type	and	
extent	 of	 the	 surgical	 procedure.11,13,27	 Unfortunately,	 correlation	
between	 the	presurgical	 and	postsurgical	 IVR	values	could	not	be	
estimated	in	this	study	as	presurgical	PK	profiles	were	not	available.
The	effects	observed	in	this	study	that	increasing	surgery	dura‐
tion	is	linked	to	decreased	CL	of	FVIII,	is	possibly	indicative	of	an	en‐
hanced	production	or	release,	or	decreased	clearance	of	FVIII	(and	
possibly	primarily	of	VWF)	to	safeguard	hemostasis	during	 longer‐
lasting	hemostatic	challenges	with	greater	tissue	damage.	Patients	in	
ASA	class	III	or	IV	showed	a	decreased	FVIII	CL	compared	to	patients	
in	ASA	class	 II.	 This	 can	possibly	be	 linked	 to	earlier	 findings	 that	
patients	with	comorbidities	exhibit	higher	VWF	and	FVIII	 levels.23 
However,	as	FVIII	baseline	levels	are	included	in	this	population	PK	
model,	 a	 decreased	 FVIII	 clearance	 for	 these	 patients	 with	 more	
comorbidities	would	mean	 that	 their	 FVIII	 levels	would	 rise	more	
during	 the	 surgery	 than	 those	 of	 patients	 without	 comorbidities.	
This	has	not	yet	been	observed.	In	the	data	used	for	the	covariate	
analysis	no	patients	were	classified	in	ASA	class	V	(moribund	patient	
not	expected	 to	 survive	24	hrs	with	or	without	an	operation)	 and	
therefore	this	class	could	not	be	included	in	the	final	FVIII	population	
PK	model.28
F I G U R E  2  The	goodness‐of‐fit	plots	of	the	final	FVIII	population	pharmacokinetic	model	for	a	specific	VWF/FVIII	concentrate	(Haemate	
P®/Humate	P®).	A,	Population	predicted	and	B,	individual	predicted	FVIII	levels	are	compared	to	observed	FVIII	levels.	Conditional	weighted	
residuals	(CWRES)	representing	the	difference	between	the	observed	and	predicted	FVIII	levels	are	compared	to	the	C,	population	predicted	
levels	and	D,	time	before/after	surgery.	The	individual	data	(black	circles)	are	visualized	as	a	trend	line	(blue	solid	line)	that	approximates	the	
line	of	identity	(black	solid	line).	The	blue	line	should	be	close	to	the	line	of	identity,	indicating	that	no	bias	is	present	in	the	pharmacokinetic	
model.	FVII,	factor	VIII;	VWD,	von	Willebrand	factor
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The	 interaction	 between	VWF	 and	 FVIII	 is	 complex,	 consid‐
ering	the	variations	in	the	VWF‐interactive	region	located	on	the	
light	chain	of	FVIII	and	possible	underlying	genetic	mutations.29,30 
Since	VWF	acts	as	a	chaperone	for	FVIII,	the	observed	effect	of	
higher	 VWF:Act	 levels	 resulting	 in	 decreased	 FVIII	 clearances	
seems	logical.31	Nonetheless,	it	should	be	noted	that	the	influence	
of	VWF:Act	on	FVIII	 in	this	PK	model	 is	only	based	on	the	mea‐
sured	VWF:Act	levels,	which	were	assumed	to	be	constant	until	the	
next	measured	level,	while	in	fact	VWF:Act	levels	are	expected	to	
change	constantly	over	time	after	the	administration	of	the	VWF/
FVIII	 concentrate.	 Furthermore,	 the	 high	 relative	 standard	 error	
(RSE	=	51%)	of	the	parameter	estimate	describing	the	relationship	
implies	that	this	observation	may	be	inaccurately	estimated.	This	
inaccuracy	can	be	caused	by	the	heterogeneity	of	VWD	types	or	
the	 absence	 of	 sufficient	 data	 to	 describe	 this	 association	 fully.	
The	effect	of	VWF:Ag	on	FVIII	PK	was	also	evaluated;	however,	
against	 expectations	 this	 influence	 was	 insignificant	 (Objective	
Function	Value	−3.54,	P	=	.05).
Remaining	covariates	included	in	the	covariate	analysis	showed	
no	significant	associations	with	PK	parameters	present	in	the	final	
FVIII	 PK	model.	Minor	 or	 major	 surgery	 severity	 was	 identified	
as	a	significant	covariate;	however,	the	ASA	classification	system	
and	surgery	duration	achieved	a	higher	statistical	 significance	 in	
the	multivariate	 analysis.	 Von	Willebrand	 disease	 type	was	 also	
expected	 to	 have	 a	 significant	 influence	 on	 the	 PK	 parameters.	
During	 univariate	 analysis,	 this	 covariate	 showed	 a	 significant	
association	with	CL,	 as	 type	2	 and	 type	3,	 respectively,	 showed	
a	 54%	 and	 74%	 higher	 clearance	 relative	 to	 type	 1	 patients.	
However,	this	effect	was	not	significant	when	the	other	covariates	
were	also	 included	 in	 the	model.	An	earlier	 study	evaluating	 the	
PK	of	the	VWF/FVIII	concentrate	in	elective	surgery	also	showed	
no	difference	between	VWD	types	and	 the	PK	of	 individual	pa‐
tients.14	However,	we	cannot	directly	compare	this	study	with	our	
current	study,	as	a	different	PK	approach	was	used	and	a	different	
loading	dose	was	 administrated.	One	possible	 explanation	 could	
be	that	VWD	type	has	less	effect	on	the	FVIII	clearance	than	ex‐
pected	 after	 administration	 of	 VWF/FVIII	 concentrate	 as	 (func‐
tional)	VWF	is	simultaneously	administrated.	On	the	other	hand,	it	
should	be	noted	that	the	majority	of	the	patients	included	in	this	
population	PK	model	were	type	1	and	2A	and	2M	patients	and	that	
the	model	contains	fewer	data	on	other	VWD	types,	for	example,	
the	data	of	only	eight	VWD	type	2B,	eight	type	2N,	and	eight	type	
3	patients.	Therefore,	the	model	is	expected	to	be	less	applicable	
to	 these	 patients.	 Patient	 characteristics	 height,	 age,	 sex,	 blood	
group,	and	renal	functioning	and	hepatic	functioning	were	not	as‐
sociated	with	any	PK	parameters	in	the	final	FVIII‐based	PK	model	
for	this	VWF/FVIII	concentrate.
The	large	estimated	IIV	in	CL	indicates	a	clinically	relevant	vari‐
ability	in	FVIII	clearance	after	administration	of	this	specific	VWF/
FVIII	 concentrate	 between	 VWD	 patients.	 The	 estimated	 IIV	 of	
CL	 became	 smaller	 when	 interoccasion	 variability	 was	 taken	 into	
account.	 The	 latter	 quantifies	 the	 intrapatient	 variability	 of	 CL.	
Unfortunately,	 inclusion	of	 interoccasion	variability	on	CL	resulted	
in	an	unstable	model	and	 it	was	 therefore	excluded.	The	 large	 IIV	
on	CL	could,	however,	be	partially	explained	by	introduction	of	the	
statistically	 significant	 covariates.	 However,	 after	 reestimation	 of	
the	PK	parameters	 using	both	 subsets,	 IIV	on	CL	 increased	 again.	
This	can	be	explained	by	the	fact	that	the	validation data set	differed	
from	the	index data set as the validation set	was	not	composed	ran‐
domly	from	all	data,	but	solely	included	data	from	one	center	during	
a	certain	period.	Differences	between	the	data	sets	included	lower	
average	surgery	durations,	a	higher	percentage	of	patients	 in	ASA	
class	II,	less	tranexamic	acid	administration,	and	fewer	patients	with	
blood	group	O	in	the	validation	data	set.	Moreover,	one	patient	with	
a	genetically	proven	VWD	type	1	Vicenza,	which	is	associated	with	a	
high	clearance,	was	present	in	this	data	set.	Overall,	clearance	in	this	
validation	subset	was	highly	variable.
A	limitation	of	the	study	is	that	the	developed	PK	model	could	
not	distinguish	endogenous	FVIII	from	exogenous	FVIII,	as	it	is	not	
possible	 yet	 to	 detect	 endogenous	FVIII	 as	 a	 separate	 entity.	 The	
terminal	half‐life	calculations	can	be	misleading,	because	of	subse‐
quent	 increases	 in	 endogenous	 FVIII	 after	 increase	 of	 exogenous	
and	 endogenous	 VWF	 after	 administration	 of	 this	 specific	 VWF/
FVIII	concentrate	in	the	perioperative	period.32,33 The median calcu‐
lated	FVIII	half‐life	of	57.7	h	is	compatible	with	a	rise	in	endogenous	
FVIII,	as	this	 is	 longer	than	the	generally	reported	FVIII	half‐life	of	
approximately	12	h.
The	population	PK	of	FVIII	after	perioperative	dosing	of	the	spe‐
cific	VWF/FVIII	concentrate	in	patients	diagnosed	with	VWD	can	be	
adequately	described	by	the	model	outlined	in	this	paper.	Increased	
F I G U R E  3  Prediction‐corrected	visual	predictive	check	(VPC)	
of	the	final	FVIII‐based	pharmacokinetic	model	of	a	specific	VWF/
FVIII	concentrate	(Haemate	P®/Humate	P®).	The	median	(red	line)	
and	95%	CI	(blue	lines)	of	the	observed	data	are	plotted	against	the	
simulated	data	(n	=	1000)	indicated	as	highlighted	areas	(red	area:	
median;	blue	area:	95%	prediction	interval).	Individual	observations	
in	the	data	are	shown	as	black	dots.	A	model	predicts	the	
concentrations	adequately	when	the	blue	and	red	lines	run	through	
the	corresponding	areas	CI,	confidence	interval;	FVIII,	factor	VIII;	
VWF,	von	Willebrand	factor
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VWF	activity	or	surgery	duration	and	classification	in	a	higher	ASA	
class	are	correlated	with	a	decrease	 in	FVIII	CL.	As	 individual	pre‐
dicted	FVIII	over	time	profiles	can	be	established	using	this	model,	
this	could	be	a	 first	step	 into	 the	direction	of	PK‐guided	dosing	 in	
VWD	patients	undergoing	surgery	treated	with	this	specific	VWF/
FVIII	 concentrate.	With	 the	 developed	model	 the	 FVIII	 levels	 can	
be	tailored	to	the	individual	patient,	which	is	especially	useful	when	
only	FVIII	targets	apply.	Development	of	new	population	PK	models	
for	the	various	other	VWF/FVIII	concentrates	is	necessary	as	the	PK	
of	these	concentrates	differs,	because	of	varying	VWF/FVIII	ratios	
and	multimer	patterns.	 Furthermore,	 a	VWF‐based	population	PK	
model	for	this	specific	concentrate	is	currently	under	development,	
and	 the	 ultimate	 goal	 is	 to	 provide	 a	model	 describing	 both	VWF	
and	FVIII	and	the	VWF	and	FVIII	interaction,	to	facilitate	PK‐guided	
dosing	based	on	VWF	as	well	as	FVIII	 levels.	Eventually	 this	over‐
all	approach	may	result	in	more	accurate	individualized	therapy	and	
therefore	in	increased	quality	and	cost‐effectiveness	of	care	for	pa‐
tients	with	VWD.
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